Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial

Objectives Health‐related quality of life (HRQoL) is particularly important during maintenance therapy (MT) in newly diagnosed multiple myeloma post‐transplant, when disease symptoms are limited. Methods We assessed HRQoL in patients randomised to 26 cycles of MT (ixazomib vs placebo) in TOURMALINE‐...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of haematology 2020-05, Vol.104 (5), p.443-458
Hauptverfasser:	Schjesvold, Fredrik, Goldschmidt, Hartmut, Maisnar, Vladimir, Spicka, Ivan, Abildgaard, Neils, Rowlings, Philip, Cain, Lauren, Romanus, Dorothy, Suryanarayan, Kaveri, Rajkumar, Vincent, Odom, Dawn, Gnanasakthy, Ari, Dimopoulos, Meletios
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Boron Compounds - administration & dosage Boron Compounds - adverse effects Boron Compounds - therapeutic use Combined Modality Therapy Diarrhea Female Glycine - administration & dosage Glycine - adverse effects Glycine - analogs & derivatives Glycine - therapeutic use Hematopoietic Stem Cell Transplantation HRQoL Humans ixazomib maintenance Maintenance Chemotherapy Male Medication Adherence Middle Aged Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - epidemiology Multiple Myeloma - mortality Multiple Myeloma - therapy Nausea Patient Reported Outcome Measures Peripheral neuropathy placebo‐controlled Quality of Life Statistical analysis TOURMALINE‐MM3 Toxicity Treatment Outcome Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!